|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07K 16/00 | |
| G01N 31/00 | |||
| C07K 1/00 | |||
| A61P 37/00 | |||
| C07K 16/24 |
| (11) | Number of the document | 2089428 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07852953.4 |
| Date of filing the European patent application | 2007-10-25 | |
| (97) | Date of publication of the European application | 2009-08-19 |
| (45) | Date of publication and mention of the grant of the patent | 2013-11-20 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2007/022622 |
| Date | 2007-10-25 |
| (87) | Number | WO 2008/057240 |
| Date | 2008-05-15 |
| (30) | Number | Date | Country code |
| 855104 P | 2006-10-27 | US |
| (72) |
BORHANI, David W., US
FRAUNHOFER, Wolfgang, US
KRAUSE, Hans-Juergen, DE
KOENIGSDORFER, Anette, DE
WINTER, Gerhard, DE
GOTTSCHALK, Stefan, DE
|
| (73) |
AbbVie Biotechnology Ltd,
Clarendon House 2, Church Street, HM 11 Hamilton,
BM
|
| (54) | CRYSTALLINE ANTI-HTNFALPHA ANTIBODIES |
| CRYSTALLINE ANTI-HTNFALPHA ANTIBODIES |